MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.870
+0.010
+0.26%
After Hours: 3.890 +0.02 +0.52% 19:58 03/05 EST
OPEN
3.850
PREV CLOSE
3.860
HIGH
3.900
LOW
3.160
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
11.82
52 WEEK LOW
1.938
MARKET CAP
40.29M
P/E (TTM)
-1.9406
1D
5D
1M
3M
1Y
5Y
InvestorNewsBreaks - Moleculin Biotech Inc. (NASDAQ: MBRX) Secures $78M in Underwritten Public Offering
Mar 05, 2021 (Investor Brand Network via COMTEX) -- Moleculin Biotech (NASDAQ: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug...
Investor Brand Network · 1d ago
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company's board of direct...
GlobeNewswire · 02/24 14:00
BRIEF-Moleculin Biotech Says On Feb 16, Co Received Letter From Nasdaq Notifying Co That It Had Regained Compliance With Nasdaq Listing Rule
reuters.com · 02/19 22:30
Underwriters exercise over-allotment option in Moleculin offering
Moleculin Biotech (MBRX) announces that the underwriters of its recent public offering have exercised their option to purchase an additional 2.14M shares at the public offering price of $4.75 per
Seekingalpha · 02/10 21:45
Moleculin Announces Full Exercise of Over-Allotment Option
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its public off...
PR Newswire · 02/10 21:15
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group
In a report issued on March 26, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $18.00. The
SmarterAnalyst · 02/09 09:09
Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases
PR Newswire · 02/08 12:30
Moleculin Biotech's annamycin brings 100% survival rate in osteosarcoma lung metastases in animals
Moleculin Biotech (MBRX) announces that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.In addition to the preclinical study results announced on February
Seekingalpha · 02/05 13:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBRX. Analyze the recent business situations of Moleculin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MBRX stock price target is 21.67 with a high estimate of 29.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 727.71K
% Owned: 6.99%
Shares Outstanding: 10.41M
TypeInstitutionsShares
Increased
2
18.86K
New
12
-20.87K
Decreased
7
63.76K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.